TABLE 4.
Changes in blood test results between CAS/IMB administration or hospitalization and 3–5 days after administration/hospitalization
| CAS/IMB group | Non‐CAS/IMB group | |
|---|---|---|
| WBC (/μL) | 400 (−855 to 1860) | −1380 (−1880 to 50) |
| Hb (g/dL) | 0.05 (−0.55 to 0.33) | −0.10 (−0.60 to −0.10) |
| Plt (×10 000/μL) | 1.40 (−4.20 to 5.60) | −0.70 (−4.60 to 0.30) |
| CRP (mg/L) | −0.48 (−1.4 to 0.86) | 0.31 (−0.26 to 2.46) |
| D‐dimer (μg/mL) | −0.05 (−1.83 to 0.08) | −0.1 (−0.99 to 0.40) |
Note: None of the parameters differed significantly between the two groups. Values are listed in median and inter‐quartile ranges.
Abbreviations: CAS/IMB, casirivimab and imdevimab; CRP: C‐reactive protein; Hb, hemoglobin; Plt, platelet count; WBC, white blood cell count.